Eli Lilly CEO David Ricks made a public case this week for Medicare to cover obesity drugs, arguing that coverage would open access for patients who cannot afford treatment on their own. Lilly is making that case while expanding manufacturing capacity ahead of a wider rollout of its Foundayo pill, and Novo Nordisk is charting its own path with new drugs planned beyond weight loss. Both companies are shaping how far this treatment category can grow, even as analysts debate what Novo's stock is worth today.
Ricks framed the issue in plain terms: obesity is a disease, and Medicare's current rules exclude weight-loss treatment from standard coverage, leaving many older patients to pay out of pocket for drugs that can cost more than a thousand dollars a month. He argued that expanding coverage would not just help patients afford treatment, it would recognize obesity as a medical condition deserving the same treatment as diabetes or heart disease. If Medicare does move in this direction, it could reshape who has access to these drugs and how quickly the market for them grows. For now, the change remains a proposal, not a policy, and any shift would likely take time to work through Congress and federal agencies.
While Ricks makes his case in Washington, Lilly is preparing for what happens if broader coverage arrives. The company is expanding manufacturing capacity ahead of a wider rollout of its Foundayo pill, a move that signals confidence in both the drug's approval path and its eventual demand. Building capacity early can help avoid the kind of supply shortages that have affected injectable GLP-1 drugs since demand outpaced production. For patients who prefer a pill over an injection, this expansion could mean shorter waits once Foundayo becomes more widely available.
Across the industry, Novo Nordisk is making its own bet on the future, and it looks different from Lilly's approach. The company is aiming to launch more than five blockbuster drugs in the coming years, a plan meant to broaden its pipeline well beyond its current lineup of weight-loss and diabetes treatments. Diversifying this way would reduce Novo's reliance on Wegovy and Ozempic, two products that have driven most of its recent growth. It also reflects a longer view, since no single drug category stays dominant forever, and a broader pipeline gives Novo more ways to compete as the field gets more crowded.
That kind of diversification is not just strategic, it is something investors are actively demanding. Novo Nordisk faces pressure from shareholders who want to see growth beyond its weight-loss drug business, particularly as competitors close the gap and pricing pressure builds across the category. Investors have grown used to Novo's rapid growth over the past few years, and they are now asking what comes next once that growth slows. The pipeline expansion Novo has outlined is, in part, a direct response to that pressure.
That pressure has spilled into a broader debate among analysts about what Novo's stock is actually worth right now. Some argue the stock looks undervalued given the company's pipeline and market position, while others see a real reset underway as competition intensifies and the easy growth of the past few years fades. The disagreement comes down to how much weight to put on Novo's past performance versus the uncertainty ahead. For investors and patients alike, the outcome of that debate will shape how much capital Novo has to invest in the new drugs it says it wants to bring to market.
None of this changes what a patient should do today, but it does show where the category is heading, toward wider insurance access and tighter competition. If you currently rely on GLP-1 treatment, it may help to watch how the Medicare coverage discussion develops, since a policy shift could directly affect what you pay. It also makes sense to watch how Novo's expanded pipeline takes shape, since a broader lineup could change pricing and availability well beyond weight-loss drugs. Two decisions, still unfolding, are worth following closely rather than acting on right now.
Key details
David Ricks is pushing Medicare to cover obesity drugs, which could widen access if…
Lilly is expanding manufacturing capacity ahead of a wider rollout of its Foundayo pill.
Novo Nordisk plans to launch more than five blockbuster drugs to broaden its pipeline.
Novo Nordisk faces investor pressure to grow beyond its weight-loss drug business.
Analysts are debating whether Novo Nordisk's stock is undervalued or facing a real…
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.